This blockade led to reduced expression of IL-19-regulated genes such as TGF-β, Matrix Metalloproteinase-1 (MMP-1), CXCR4, and Cyclin B (CCNB1), highlighting the therapeutic potential of IL-19 inhibition in esophageal cancer [38]. The gene discussed is CXCR4; the disease is esophageal cancer.